Cytokinetics, Incorporated Shares Acquired by Fisher Asset Management LLC
| CYTK Stock | USD 46.00 1.45 3.06% |
About 62% of Cytokinetics' investor base is looking to short. The analysis of the overall investor sentiment regarding Cytokinetics suggests that many traders are alarmed. Cytokinetics' investing sentiment shows overall attitude of investors towards Cytokinetics.
Cytokinetics |
Fisher Asset Management LLC lifted its stake in Cytokinetics, Incorporated by 1.5 percent in the 3rd quarter, according to its most recent Form 13F filing with the Securities Exchange Commission. The firm owned 542,284 shares of the biopharmaceutical companys stock after purchasing an additional 7,764 shares during the period. Fisher Asset
Read at thelincolnianonline.com
 |
Cytokinetics Fundamental Analysis
We analyze Cytokinetics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cytokinetics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cytokinetics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Revenue
Revenue Comparative Analysis
Cytokinetics is currently under evaluation in revenue category among its peers. Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Cytokinetics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Cytokinetics stock to make a market-neutral strategy. Peer analysis of Cytokinetics could also be used in its relative valuation, which is a method of valuing Cytokinetics by comparing valuation metrics with similar companies.
Peers
Cytokinetics Related Equities
| XFOR | X4 Pharmaceuticals | 8.11 | ||||
| BPMC | Blueprint Medicines | 6.80 | ||||
| PLRX | Pliant Therapeutics | 5.52 | ||||
| RLAY | Relay Therapeutics | 4.92 | ||||
| RVMD | Revolution Medicines | 4.25 | ||||
| AMLX | Amylyx Pharmaceuticals | 3.80 | ||||
| BDTX | Black Diamond | 3.61 | ||||
| DYN | Dyne Therapeutics | 3.34 | ||||
| ARVN | Arvinas | 2.55 | ||||
| ABOS | Acumen Pharmaceuticals | 1.59 | ||||
| EWTX | Edgewise Therapeutics | 0.83 | ||||
| INZY | Inozyme Pharma | 0.83 | ||||
| STOK | Stoke Therapeutics | 1.75 | ||||
| TERN | Terns Pharmaceuticals | 1.86 |
Check out Cytokinetics Hype Analysis, Cytokinetics Correlation and Cytokinetics Performance. For more information on how to buy Cytokinetics Stock please use our How to buy in Cytokinetics Stock guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytokinetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.